1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)

BACKGROUND: IBR is a Bruton’s tyrosine kinase inhibitor, and plays a key role in the treatment of CLL. In randomized clinical trials, <1% of IBR-treated CLL patients developed IFIs. However, several IFIs were reported with real-life use of IBR. METHODS: This is a retrospective observational study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Frei, Michael, Aitken, Samuel L, Jain, Nitin, Thompson, Philip, Wierda, William G, Kontoyiannis, Dimitrios P, DiPippo, Adam
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6808854/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1582
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars